StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Other Pharmaceutical Products — U.S. sales by Year

Other Pharmaceutical Products — U.S. sales ($M) ($M)

Merck Other Pharmaceutical Products — U.S. sales: $676M in FY2025, up 5.6% from a year earlier.

Latest, FY2025
676
Period ended Dec 31, 2025
Change on a year earlier
+5.6%
640 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Other Pharmaceutical (8) | 2,917 | 2,590 | 13 | 676 | 640 | 6 | 2,244 | 1,951 | 15”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up other Pharmaceutical Products — U.S. sales

Cite this data

StockData. (2026). Merck Other Pharmaceutical Products — U.S. sales ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-other-pharma-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.